Timothy Adams Purchases 300,000 Shares of SS Innovations International (NASDAQ:SSII) Stock

SS Innovations International, Inc. (NASDAQ:SSII) Director Timothy Adams purchased 300,000 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was bought at an average price of $3.99 per share, with a total value of $1,197,000.00. Following the acquisition, the director directly owned 5,331,902 shares in the company, valued at approximately $21,274,288.98. This represents a 5.96% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

SS Innovations International Trading Up 9.7%

SSII stock opened at $4.85 on Thursday. The company has a market cap of $942.63 million and a P/E ratio of -80.83. SS Innovations International, Inc. has a 52 week low of $3.02 and a 52 week high of $22.42. The company’s 50-day moving average price is $4.80 and its 200 day moving average price is $6.05.

SS Innovations International (NASDAQ:SSII) last issued its earnings results on Tuesday, March 10th. The company reported ($0.01) earnings per share (EPS) for the quarter. SS Innovations International had a negative net margin of 28.54% and a negative return on equity of 29.76%. The company had revenue of $14.53 million during the quarter.

Key SS Innovations International News

Here are the key news stories impacting SS Innovations International this week:

• Positive Sentiment: Multiple insiders bought material amounts of stock (CEO Srivastava ~498,753 shares; Director Timothy Adams 300,000 shares; Director Frederic Moll 501,253 shares), totaling ~1.3M shares and ~ $5.2M of purchases — a strong signal of management confidence. SEC filing: Srivastava purchase SEC filing: Adams purchase SEC filing: Moll purchase
• Positive Sentiment: Company reported Q4 and FY‑2025 results highlighting stronger SSi Mantra installations, procedures and revenue growth — supports the growth narrative as the company scales device adoption. GlobeNewswire: Q4/FY2025 results
• Positive Sentiment: Completed a private placement raising approximately $18.6M (5.77M shares, institutional and insider participation) to fund U.S./EU expansion and working capital while awaiting regulatory milestones. The financing reduces near‑term cash risk. GlobeNewswire: Private placement
• Neutral Sentiment: Some institutional investors have added positions recently, which may provide longer‑term support but won’t necessarily reduce short‑term volatility. QuiverQuant: placement/ownership summary
• Negative Sentiment: Reported EPS of ($0.01) for the quarter with a negative net margin (~32%) and negative ROE (~34%) — profitability remains a headwind and could limit multiple expansion until margins improve. GlobeNewswire: Q4/FY2025 results
• Negative Sentiment: The private placement issues 5.77M shares plus unregistered securities/warrants, creating dilution and potential downward pressure on the stock despite the capital raise. GlobeNewswire: Private placement terms
• Negative Sentiment: Company progress depends on regulatory outcomes (FDA 510(k) review and CE marking). Timing and approval risk keep shares volatile until clear regulatory wins occur. GlobeNewswire: regulatory timeline

Institutional Investors Weigh In On SS Innovations International

A number of large investors have recently added to or reduced their stakes in SSII. Geode Capital Management LLC purchased a new position in SS Innovations International during the 2nd quarter valued at about $122,000. Inspire Investing LLC purchased a new stake in shares of SS Innovations International in the third quarter valued at about $240,000. Envestnet Asset Management Inc. purchased a new stake in shares of SS Innovations International in the third quarter valued at about $71,000. PNC Financial Services Group Inc. acquired a new stake in shares of SS Innovations International in the third quarter valued at approximately $56,000. Finally, Handelsbanken Fonder AB acquired a new stake in shares of SS Innovations International in the third quarter valued at approximately $714,000.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SS Innovations International in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, SS Innovations International has a consensus rating of “Sell”.

SS Innovations International Company Profile

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015. AVRA Medical Robotics, Inc was founded in 2015 and is based in Orlando, Florida.